Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Updates in Medicine REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio Phase 3a RCT in 1206 adults with T2D (BMI 27, HbA1c 710%) Instagram Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial The Lancet Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library REDEFINE 1 Trial Finds CagrilintideSemaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients Applied Clinical Trials Online